



REMIIDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805

Reg.Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



To,
Listing Department
BSE Limited
P. J Tower, Dalal Street,
Mumbai- 400001

Scrip Code: 539561

Sub: Outcome of the Board Meeting held on 27.05.2024

Dear Sir,

This is to inform you that the Board of Directors of the Company at its meeting held on May 27, 2024 has inter alia transacted the following business:

1. Financial Results
 - a. Approved the Audited Standalone Financial Results for the quarter and year ended March 31, 2024

Pursuant to Clause 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR) Regulations, 2015), please find enclosed herewith the Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2024 together with the Report of the Statutory Auditors in respect of the same.
 - b. Pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2015, we hereby confirm that the Auditor's Report on Audited Financial Results for the year ended March 31, 2024 approved at the board meeting held today i.e. 27.05.2024, is with unmodified opinion.
2. Subject to the approval of the members in the Annual General Meeting and appropriate authorities, the Board has considered, approved and recommended a Bonus Issue of 3 Equity Shares of Re. 1/- each fully paid up for every 1 Equity Share of Re. 1/- each fully paid up held as on the Record date decided for this purpose. The Bonus Shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing

Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the issue and allotment of such Bonus Shares.

The details as required for Bonus Issue of Shares under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI Circular SEBI/HO/CFD/CFD- PoD-1/P/CIR/P/2023/123 dated July 13, 2023 is as below:

Sr. No.	Particulars	Disclosure
a.	Type of Securities proposed to be issued	Equity Shares
b.	Type of Issuance	Bonus Issue
c.	Total number of securities proposed to be issued or the total amount for which the securities will be issued	30,24,00,000 Equity Shares of Re. 1/- each fully paid up amounting to Rs. 30,24,00,000/-.
Additional Details		
d.	Whether bonus is out of free reserves created out of profits or share premium account	Yes, The Bonus Equity Shares will be issued out of Retained Earnings of the Company available as at March 31, 2024.
e.	Bonus ratio	3:1 (i.e., Three Equity Shares of Re. 1/- each fully paid up for every One Equity Share of Re. 1/- each fully paid up held as on the record date decided for this purpose).
f.	Details of share capital - pre and post bonus issue	Pre-Bonus Issue- The Paid-Up Equity Share Capital as on date is Rs. 10,08,00,000/- divided into 10,08,00,000 Equity Shares of Re. 1/- each. Post-Bonus Issue- The Paid-Up Equity Share Capital will be Rs. 40,32,00,000/- divided into 40,32,00,000 Equity Shares of Re. 1/- each.
g.	Free reserves and/ or share premium required for implementing the bonus issue	Retained Earnings - Rs. 30,24,00,000/-

h.	Free reserves and/ or share premium available for capitalization and the date as on which such balance is available	As on March 31, 2024, Retained Earnings amount available is Rs. 32,87,77,556.
i.	Whether the aforesaid figures are audited	Yes, the aforesaid figures are as per the audited financial statements.
j.	Estimated date by which such bonus shares would be credited/dispatched	Subject to obtaining shareholders' approval and other approvals, the Bonus shares will be credited/dispatched within 2 months from the date of Board approval i.e., on or before 26 th July, 2024.

3. Subject to the approval of the members in the Annual General Meeting and appropriate authorities, the Board has considered, approved and recommended to increase the Authorized Share Capital of the Company from the existing Authorised Capital of Rs. 30,00,00,000/- (Rupees Thirty Crores Only) divided into 30,00,00,000 (Thirty Crores) Equity Shares of Re. 1/- (Rupee One Only) each to Rs. 42,00,00,000/- (Rupees Forty Two Crores Only) divided into 42,00,00,000 (Forty Two Crores) Equity Shares of Re. 1/- (Rupee One Only) each and consequent alteration of Capital Clause V of Memorandum of Association of the Company.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and SEBI Circular SEBI/HO/CFD/CFD- PoD-1/P/CIR/P/2023/123 dated July 13, 2023 is as below:

“The Authorized Share Capital of the Company is Rs. 42,00,00,000/- (Rupees Forty Two Crores Only) divided into 42,00,00,000 (Forty Two Crores only) Equity Shares of Re. 1/- (Rupee One only) each with the rights, privileges and conditions attaching thereto as are provided by the regulations of the Company for capital of the Company for the time being, with power to increase and reduce the capital of the Company, and to divide the shares in the capital for the time being into several classes and to attach thereto respectively such preferential, deferred, qualified or special rights, privileges or conditions as may be determined by or in accordance with the regulations of the Company and to vary, modify or abrogate any such rights, privileges or conditions in such manner as may for the time being be provided by the regulations of the Company.”

4. Record Date for Bonus Issue of Equity Shares in a ratio of 3:1 i.e., Three Equity Shares of Re. 1/- each fully paid up for every One Equity Share of Re. 1/- each fully paid up held as on the record date decided for this purpose **(if approved by the shareholders in the Annual General Meeting) is Saturday, 06th July, 2024.**

5. Approved Draft Notice for convening the Annual General Meeting (AGM) for above purpose.
6. An Annual General Meeting of the Company to be convened on **Wednesday, 26th June, 2024 at 11.00 A.M**, through Video Conferencing/ Other Audio Visual Means (OAVM) in compliance with the applicable provisions of the Companies Act, 2013 read with MCA General Circular No. 14/2020 dated 08.04.2020, General Circular No. 17/2020 dated 13.04.2020, General Circular No. 22/2020 dated 15.06.2020, General Circular No. 33/2020 dated 28.09.2020, General Circular No. 39/2020 dated 31.12.2020, General Circular No.10/2021 dated 23.06.2021, General Circular No. 20/2021 dated 08.12.2021, General Circular No. 3/2022 dated 05.05.2022 and General Circular No. 10/2022 dated 28.12.2022 and General Circular No. 09/2023 dated 25.09.2023 to transact the above business.
7. Ms. Riddhi Shah (Membership No. 20168, CP No. 17035), Practicing Company Secretary is appointed as the Scrutinizer for conducting “Remote E voting” and “E-voting during the AGM” process for ensuing Annual General Meeting.
8. Cut Off date for determining shareholders eligible to vote by electronic means for the purpose of Annual General Meeting scheduled on 26th June, 2024 shall be **19th June, 2024**.

The Board Meeting concluded at 9.00 p.m.

We request you to kindly take the note of the above and update the same in your records.

Thanking You,

Yours faithfully,

For Remedium Lifecare Limited

Adarsh Munjal
Whole Time Director
Encl: As above.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West, Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

INDEPENDENT AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To,
The Board of Directors
Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)

Opinion

We have audited the accompanying annual financial results of **Remedium Lifecare Limited (formerly known as Roxy Exports Limited)** (hereinafter referred to as the "Company") for the year ended 31st March, 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31st March, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West. Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West. Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31st March, 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For TAORI SANDEEP & ASSOCIATES
Chartered Accountants
Firm Registration No. : 007414C

Place: Mumbai
Date: 27th May, 2024
UDIN: 24048920BKBIXI5276



A handwritten signature in blue ink, appearing to read "Atul".

CA Atul Jain
(Partner)
M. No. : 048920

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059

E-mail: info@remediumlifecare.com;

CIN: L24100MH1988PLC343805

Statement of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2024

(₹ in Lakh - Except per Share Data)

Particulars	Quarter Ended			Year Ended	
	31st March, 2024	31st Dec, 2023	31st March, 2023	31st March, 2024	31st March, 2023
I. Revenue from Operations	140849.37	183417.83	7557.96	404170.67	50983.66
II. Other Income	289.27	1411.60	0.00	2108.11	0.00
III. Total Income (I + II)	141138.64	184829.43	7557.96	406278.78	50983.66
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	142230.54	189160.96	7187.08	412728.50	41730.44
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	1931.29	-11321.59	170.68	-12590.97	7655.24
Employee Benefits Expenses	18.31	17.05	28.68	84.27	98.33
Finance Costs	384.72	2.59	-9.93	387.30	-7.55
Depreciation and amortisation expenses	1.41	1.34	1.40	5.67	15.08
Other Expenses	172.01	91.39	461.20	618.59	752.53
Total Expenses (IV)	144738.27	177951.73	7839.11	401233.35	50244.07
V. Profit/(Loss) before exceptional items and tax (III-IV)	-3599.64	6877.70	-281.15	5045.42	739.60
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-3599.64	6877.70	-281.15	5045.42	739.60
VIII. Tax Expense					
(1) Current tax	1,774.34	0.00	197.74	1,774.34	197.74
(2) Deferred tax	-1.93	0.00	-0.75	-1.93	-0.75
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
Total Tax	1772.41	0.00	196.99	1772.41	196.99
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-5372.04	6877.70	-478.13	3273.02	542.61
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-5372.04	6877.70	-478.13	3273.02	542.61
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	-5372.04	6877.70	-478.13	3273.02	542.61
XVI. Earnings per equity share (for continuing operation):					
(1) Basic	-149.22	34.12	-13.28	90.92	15.07
(2) Diluted	-149.22	34.12	-13.28	90.92	15.07
XVII. Earnings per equity share (for discontinued operation):					
(1) Basic	0.00	0.00	-13.28	0.00	15.07
(2) Diluted	0.00	0.00	-13.28	0.00	15.07
XVIII. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	-149.22	0.00	-13.28	90.92	15.07
(2) Diluted	-149.22	0.00	-13.28	90.92	15.07

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on May 27, 2024. The Statutory Auditors have carried out their audit for the above results.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- Income tax in Quarter 4 represent income tax provision for full year.
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.
- Figures of the quarter ended 31st March, 2024 and 31st March, 2023 are balancing figures between audited figures in respect of full financial year and the year to date figures upto third quarter of the relevant financial year which were subject to limited review by the auditors.

For Remedium Lifecare Limited


ADARSH MUNJAL
 (Whole Time Director)
 DIN : 07304004



Date: 27.05.2024
 Place : Mumbai

REMEDIUM LIFECARE LIMITED

**REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar
Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805**

Statement of Audited Standalone Balance Sheet as at

(₹ in Lakhs)

Particulars	31st March, 2024	31st March, 2023
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	4.70	7.81
(b) Capital Work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intangible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financials Assets-		
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other(to be specified)	-	-
(i) Deferred tax assets (net)	2.67	0.74
(j) Other non-current assets	-	-
Sub-total Non Current Assets	7.37	8.55
Current Assets		
(a) Inventories	13,323.06	732.09
(b) Financials Assets		
(i) Investments	-	-
(ii) Trade receivables	92,060.18	17,237.37
(iii) Cash and cash equivalents	27.07	24.36
(iv) Bank Balance other than (iii) above	125.32	2,161.20
(v) Loans/Advances	89,038.18	95,200.80
(vi) Others (to be specified)	211.17	57.90
(c) Current tax Assets	-	-
(d) Other current Assets	-	-
Sub-total - Current Assets	1,94,784.99	1,15,413.72
TOTAL ASSETS	1,94,792.36	1,15,422.27



EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	1,008.00	360.00
(b) Other Equity	3,287.78	676.43
Sub Total Equity	4,295.78	1,036.43
Liabilities		
Non -Current liabilities		
(a) Financials Liabilities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(iii) Other Financial liabilities (other than specified in item (b) to be specified	-	-
(b) Provisions	-	-
(c) Deffered Tax Liabilites (net)	-	-
(d) Other Non-Current Liabilities	-	-
Sub Total Non Current Liabilities	-	-
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	5,770.25	-
(ii) Trade Payables	71,228.80	8,421.76
(iii) Other Financial liabilities (other than specified in item (c) to be specified	-	-
(b) Other current liabilities	1,11,670.08	1,05,713.41
(c) provisions	1,827.45	250.67
(d) Current Tax Liabilities	-	-
Sub Total Non Current Liabilities	1,90,496.58	1,14,385.84
TOTAL EQUITY AND LIABILITES	1,94,792.36	1,15,422.27

For REMEDIUM LIFECARE LIMITED





ADARSH MUNJAL
(WHOLE TIME DIRECTOR)

DIN : 07304004

Date: 27.05.2024

Place : Mumbai

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059

E-mail: info@remediumlifecare.com;

CIN: L24100MH1988PLC343805

Audited Cashflow Statement for the Year ended on 31st March,2024

(₹ in Lakhs)

<u>Particulars</u>	LF	<u>As at 31.03.2024</u>	<u>As at 31.03.2023</u>
<u>A. Cashflow from operating activity</u>			
Net Profit / (Loss) before extraordinary items and tax		5,045.42	739.60
<u>Adjustments for:</u>			
Depreciation and amortisation		5.67	15.08
Profit on sale of FA			-
Finance Cost		387.30	3.73
Interest Income		-9.38	-
Operating profit / (loss) before working capital changes		5,429.01	758.41
<u>Changes in working capital:</u>			
<u>Adjustments for (increase) / decrease in operating assets:</u>			
Inventories		-12,590.97	7,655.24
Trade receivables		-74,779.07	-10,837.77
Other Current assets		-153.27	-42.32
Current Loans and Advances		6,219.41	-87,789.86
Non Current Loans			-
<u>Adjustments for increase / (decrease) in operating liabilities:</u>			
Trade payables		62,707.54	-4,034.53
Other current liabilities		5,964.87	96,334.45
Current provisions		1,567.56	204.11
Current Tax liabilities			-
Cashflow from extraordinary activity			
Cash Generated from operation		-11,063.93	2,247.74
Net Income tax paid		1,781.19	-197.74
<u>Net cash flow from / (used in) operating activities(A)</u>		-12,845.12	2,050.00
<u>B. Cash flow from investing activities</u>			
Capital expenditure on fixed assets, including capital advances			-4.27
Proceeds from sale of fixed assets			-
Receipt of Loans & Advances			-
Interest received		9.38	-
-- Others			-
Cash flow from extraordinary items			
Net cash flow from / (used in) investing activities (B)			-4.27
<u>C. Cash flow from financing activities</u>			
Proceeds from issue of equity shares		-	-
Proceeds from Short-term borrowings		5,770.25	-
Finance cost		-387.30	-3.73
Loan From Director		-	-
Dividends paid		-	-



Tax on dividend		
Net cash flow from / (used in) financing activities (C)	5,382.94	-3.73
Net Cash flow during the period	-2,033.17	2,042.00
Cash and cash equivalents at the beginning of the year	2,185.56	143.56
Cash and cash equivalents at the end of the year	152.39	2,185.56
Reconciliation of Cash and cash equivalents with the Balance Sheet:		
Cash and cash equivalents as per Balance Sheet	152.39	2,185.56
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 7 "Statements of Cash Flow"		
Net Cash and cash equivalents as defined in AS 7 ("Statement of Cash Flows")	152.39	2,185.56
Add: Current investments considered as part of Cash and cash equivalents (as defined in Ind AS 7 ("Statement of Cash Flows")) (Refer Note (ii) to Note 16 Current investments)		
Cash and cash equivalents at the end of the year *	152.39	2,185.56
* Comprises		
(a) Cash on hand	27.07	24.36
(b) Cheques, drafts on hand		-
(c) Balances with banks		
(i) In current accounts	125.32	2,161.20
(ii) In EEFC accounts		-
(iii) In deposit accounts with original maturity of less than 3 months		-
(iv) In earmarked accounts (give details) (Refer Note (ii) below)		-
(d) Others (specify nature)		-
(e) Current investments considered as part of Cash and cash equivalents		-
Total	152.39	2,185.56

On behalf of the Board
FOR REMEDIUM LIFECARE LIMITED



ADARSH MUNJAL
WHOLE TIME DIRECTOR
DIN : 07304004



Place: Mumbai
Date: 27.05.2024